Mast Cell Activation Syndrome Clinical Trial
Official title:
Ocular and Palpebral Manifestations of Mastocytosis (MOOMA)
Mastocytosis is a rare condition characterized by an accumulation of mast cell cells in one or more organs such as the liver, bone marrow, spleen and intestines. Its prevalence in the general population is 1 in 10,000. This pathology is due to the proliferation of a mast cell clone and the excessive release of inflammatory mediators which lead to abnormal tissue infiltration. To date, there are only a few cases reporting ocular and orbital manifestations of mastocytosis. Our prospective, interventional and single-center study consist in describing the ocular functional manifestations and ocular surface abnormalities of patients with systemic and cutaneous mastocytosis.
Patient with systemic or cutaneous mastocytosis will be included in the study. Data about organ involvement of mastocytosis will be collected. Participants will be screened with a medical and eye disease history. They will also have an eye exam. Participants will provide a tears sample. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05449444 -
Masitinib for the Treatment of Severe Mast Cell Activation Syndrome
|
Phase 2 | |
| Terminated |
NCT05652907 -
Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)
|
Phase 2 | |
| Completed |
NCT03406325 -
Mast Cell Activation Test in Allergic Disease
|